Abstract: Objective To investigate the efficacy and safety of edaravone dexborneol combined with Danhong injection in the treatment of cerebral infarction. Methods A total of 84 patients with cerebral infarction admitted to Handan Central Hospital from April 2023 to December 2024 were divided into two groups, using a random number table. Patients in the control group (n = 42) received edaravone dexborneol treatment, while those in the intervention group (n = 42) were treated with a combination of edaravone dexborneol and Danhong injection. The clinical efficacy, neurological function, activities of daily living, neurological markers, oxidative stress indicators, high-sensitivity C-reactive protein, homocysteine, hemorheological indicators, and adverse reactions were compared between the two groups. Results The total effective rate in the intervention group was higher than that in the control group (P ＜ 0.05). After 1 and 2 weeks of treatment, the National Institute of Health Stroke Scale scores, brain-derived neurotrophic factor level, high-sensitivity C-reactive protein level, homocysteine level, malondialdehyde level, superoxide dismutase level, as well as whole blood viscosity at low shear rate, whole blood viscosity at high shear rate, and plasma viscosity in the intervention group were lower than those in the control group. The modified Barthel index and vascular endothelial growth factor level were higher than those in the control group (P ＜ 0.05). Compared with pre-treatment, the aforementioned scores and indicator levels in both groups were improved after 1 and 2 weeks of treatment (P ＜ 0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Edaravone dexborneol combined with Danhong injection can improve the clinical efficacy, enhance neurological function and activities of daily living, and ameliorate oxidative stress indicators and hemorheological parameters in patients with cerebral infarction.